FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, not for consumption, not medicines. Research use policy
UK only · Prepared to order · approx. 7 days + Royal Mail Tracked 24 · No international shipping
Non-peptide research compound · Lyophilised vial

5-Amino-1MQ

Mitochondrial & metabolic biochemistry research compounds

Small-molecule methylquinolinium compound studied as an NNMT inhibitor in cell models.

£17.99 ex. VAT · per vial
Available

Prepared to order · approx. 7 days + Royal Mail Tracked 24

SKU BP-5AM1MQ-5 · ≥99% (see COA) · Lyophilised powder

For laboratory research use only. Not for human or veterinary use. Not a medicine, food supplement or cosmetic. Purchasers confirm research use, age 18+ and institutional/professional status at checkout. UK delivery only.
Data pending verification. Identity data in the specification below has been compiled for pre-launch and is awaiting verification against supplier documentation and batch COAs. Highlighted fields are unconfirmed.

5-Amino-1MQ overview

5-Amino-1-methylquinolinium is a small molecule, not a peptide; the counter-ion should be confirmed on the COA. It is supplied as a solid for in-vitro research.

Sequence
Not applicable (small molecule)
Molecular formula
C₁₀H₁₁N₂⁺ (cation; salt form per COA)
Molecular weight
≈159.2 g/mol (cation; salt form per COA)
Purity
≥99% (see COA)
Form
Lyophilised powder
Vial sizes & prices
5 mg – £17.99; 10 mg – £26.99; 20 mg – £54.49; 50 mg – £56.99 (ex. VAT)
Delivery
UK only · prepared to order (approx. 7 days) then Royal Mail Tracked 24, £5.95

5-Amino-1MQ research background

Preclinical only

Evidence status: Findings summarised here come from published cell-culture and animal research only; no controlled human studies were identified. They are not established effects in humans, have not been evaluated by the MHRA, and are provided for scientific context only. This product is supplied strictly for laboratory research and is not for human or veterinary use.

Established research

Peer-reviewed published findings, with references
Overview & discovery history
  • 5-Amino-1-methylquinolinium (5-amino-1MQ) is a small-molecule, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT), described by Neelakantan, Watowich and colleagues [1]. It is not a peptide.
Chemical identity
Sequence
Not applicable (small molecule)
Molecular formula
C₁₀H₁₁N₂⁺ (cation; salt form per COA)
Molecular weight
≈159.2 g/mol (cation; salt form per COA)
CAS number
[TO VERIFY against supplier COA – depends on salt form]
Form
Lyophilised powder
Purity
≥99% (see COA)
Format
Lyophilised vial
Vial sizes
5 mg, 10 mg, 20 mg, 50 mg

Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.

Mechanisms investigated
  • NNMT inhibition: in adipocytes, this was reported to increase intracellular NAD⁺ and SAM and to reduce lipogenesis [1].
Research areas & model types
Research areaModel typeSummary
Diet-induced obesityMouse[1][2]
Gut microbiome in diet-induced obesityMouse[3]
Human clinical research status
  • No human trials were identified. It is not an approved medicine.
Safety observations reported in studies
  • In the original mouse study, no observable adverse effects or changes in food intake were reported [1]. No human data exist.
Known limitations
  • The evidence is preclinical only, largely from one group.
Storage & handling for laboratory use

Store at −20 °C. Protect from light.

Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.

  • Allow the sealed vial to reach room temperature before opening to limit condensation.
  • Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
  • Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.

Emerging & theoretical

Unconfirmed — hypotheses & ongoing research

These are unconfirmed hypotheses and early-stage lines of enquiry, not established effects. Not evaluated by the MHRA. Not for human or veterinary use.

Hypotheses proposed by researchers

  • Researchers have proposed NNMT as a target for metabolic disease, with increased NAD⁺ and SAM flux as a possible mechanism [1][2].

Open scientific questions

  • What are its selectivity and off-target profile?

Preprints: none included (no relevant preprint could be verified). Anecdotal, user-reported or social-media material is deliberately excluded.

References

  1. Neelakantan H, Vance V, Wetzel MD et al.. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018. PubMed 29155147 · doi:10.1016/j.bcp.2017.11.007
  2. Babula JJ, Bui D, Stevenson HL et al.. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. PubMed 39161060 · doi:10.1111/dom.15879
  3. Dimet-Wiley A, Wu Q, Wiley JT et al.. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022. PubMed 35013352 · doi:10.1038/s41598-021-03670-5

Every reference was checked against PubMed (NCBI) before publication. Summaries describe published research only and are not claims of any effect in humans or animals.

Certificates of analysis

[No batch COA published yet. The certificate for each lot will be listed here and in the COA checker before release.]

Open the COA checker